Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00441662 · ClinicalTrials.gov registry record · NA

Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema

A NA study, sponsored by Wills Eye.

Completed
Registry status
NA
Development phase
170
Enrollment target

NCT00441662 is a NA study that has completed, run by Wills Eye. The registered enrollment target is 170 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00441662, a NA study, has completed, sponsored by Wills Eye.

COMPLETED
Registry status
NA
Development phase
170 participants
Enrollment target

Study Summary

Melanoma is the most common primary tumour which occurs inside the eye. For over 20-years, it has been possible, in many cases, to use local delivery of radiation to the eye to treat this type of tumour, avoiding the need to surgically remove the affected eye. This treatment, however, is often complicated by radiation-induced loss of vision, months or years after treatment. The aim of this research project is to investigate the potential prevention of radiation complications in the eye by giving anti-inflammatory medication (a long-acting steroid) in the form of a local injection around the eye at the time of treatment, and at 4-months and 8-months following treatment. This medication (named 'triamcinolone') has been successfully used to treat similar complications of diabetic eye disease, for example, and has a good safety profile. The rationale of this study is to attempt to preserve vision, in addition to preserving the eye, in patients affected by this eye tumour, and therefore preserve quality of life for these patients.

Interventions

  • DRUG Sub-Tenon triamcinolone 40mg

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2004-11
Est. Completion 2007-05
Phase NA

Sponsor

Wills Eye

59 total trials

What the Registry Record Tells You About NCT00441662

The ClinicalTrials.gov registry entry for NCT00441662 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Sub-Tenon triamcinolone 40mg is the first listed.

NCT00441662 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00441662 about?

NCT00441662 is a clinical study titled "Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema". Melanoma is the most common primary tumour which occurs inside the eye. For over 20-years, it has been possible, in many cases, to use local delivery of radiation to the eye to treat this type of tumour, avoiding the need to surgically remove the affected eye. This treatment, however, is often compl...

What is the current status of trial NCT00441662?

This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2004-11. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00441662?

The interventions under investigation include: Sub-Tenon triamcinolone 40mg (DRUG).

Who is sponsoring clinical trial NCT00441662?

This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.